Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Depressive Disorder 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 195pembrolizumab 158Pemetrexed 136Cisplatin 119durvalumab 73Paclitaxel 72osimertinib 68Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 58Magnetic Resonance Spectroscopy 50Etoposide 47Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 21Platinum 20Radiation 19amivantamab 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Psilocybin × Thoracic × 90 days × Clear all
NCT07216404 2026-05-14

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Depressive Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡